Polyakova Anna, Kuznetsova Ksenia, Moshkovskii Sergei
a Institute of Biomedical Chemistry - Personalized Medicine, Pogodinskaya Street 10, Moscow 119121, Russian Federation.
Expert Rev Proteomics. 2015;12(5):533-41. doi: 10.1586/14789450.2015.1070100. Epub 2015 Jul 15.
Cancer proteogenomics is an emerging field that aims to identify and quantify protein sequence changes associated with the cancer genome. Besides being involved in cancer development and progression, such protein variants may serve as neoantigens, which provide the T-cell response against tumors. Mass spectrometry-based proteogenomics may be a promising tool for finding neoantigens in individual specimens. It is partly based on a technical background accumulated from mass spectrometric studies of peptide ligands of major histocompatibility complex proteins. Examples of the use of mass spectrometry in neoantigen identification are reviewed in this article. Some experimental workflows are discussed, which may use shotgun and targeted proteomics for translational human studies of neoepitopes, such as cancer vaccine development and checkpoint therapy response prediction.
癌症蛋白质基因组学是一个新兴领域，旨在识别和量化与癌症基因组相关的蛋白质序列变化。除了参与癌症的发生和发展外，这些蛋白质变体可能作为新抗原，引发针对肿瘤的T细胞反应。基于质谱的蛋白质基因组学可能是在个体样本中寻找新抗原的一种有前景的工具。它部分基于从主要组织相容性复合体蛋白质的肽配体质谱研究中积累的技术背景。本文综述了质谱在新抗原鉴定中的应用实例。还讨论了一些实验工作流程，这些流程可将鸟枪法和靶向蛋白质组学用于新表位的转化性人体研究，如癌症疫苗开发和检查点治疗反应预测。
